آزمون آزمایشی OET Reading شماره 8

Text A: Case Notes – Asthma Patient

Patient: Omar Hassan, 35, M

Date: June 10, 2025

History: Diagnosed with asthma at age 15. Presents with increased wheezing and shortness of breath (SOB) triggered by pollen exposure. Symptoms worsened past week; peak flow 350 L/min (70% of predicted). Current medications: salbutamol inhaler PRN (4–6x/day), budesonide/formoterol 160/4.5 mcg BD. Non-smoker, no allergies. Works as landscaper.

Examination: RR 24, SpO2 94%, HR 88. Chest: bilateral wheeze, no crackles. No cyanosis.

Management: Added oral prednisone 40 mg OD for 5 days. Advised to avoid outdoor work during high pollen counts. Referred to respiratory specialist for uncontrolled asthma. Increased budesonide/formoterol to 320/9 mcg BD. Educated on inhaler technique and action plan. Follow-up in 2 weeks; repeat peak flow. Provided multilingual asthma resources.

Notes: Patient non-adherent to maintenance inhaler due to busy schedule. Emphasized daily use to prevent exacerbations. Contact asthma educator (ext. 320).

Text B: Medication Guidelines – Asthma Inhalers

Source: Global Initiative for Asthma (GINA), 2025

Inhaled corticosteroids (ICS) like budesonide are first-line for persistent asthma. Combine with long-acting beta-agonists (LABA) (e.g., formoterol) for moderate-to-severe cases. Dosage: budesonide/formoterol 160/4.5 mcg, 1–2 puffs BD; escalate to 320/9 mcg if uncontrolled. Short-acting beta-agonists (SABA) (e.g., salbutamol) are for acute relief (2–4 puffs PRN, max 12 puffs/day).

Administration: Use spacer with metered-dose inhalers (MDIs) to improve delivery. Rinse mouth post-ICS to prevent thrush. Side effects: hoarseness (5%), oral candidiasis (2%). Monitor adherence; non-adherence affects 60% of patients, increasing exacerbations by 50%. Nurses should train patients on technique and action plans. Pharmacists ensure correct dispensing and counseling. Annual reviews adjust therapy based on control.

Emergency: If peak flow <60% predicted or no relief after 8 puffs salbutamol, administer oral prednisone (40–50 mg OD, 5–7 days) and seek urgent care.

Text C: Referral Letter – Respiratory Specialist

To: Dr. Lisa Chen, Respiratory Clinic

From: Dr. Ahmed Zaki, GP

Date: June 11, 2025

Re: Omar Hassan, 35, M, Asthma

Dear Dr. Chen,

I am referring Mr. Hassan for evaluation of poorly controlled asthma. Diagnosed at 15, he presents with frequent wheezing and SOB, worsened by pollen. Peak flow is 350 L/min (70% predicted). Current therapy: budesonide/formoterol 160/4.5 mcg BD, salbutamol PRN (4–6x/day). I've added prednisone 40 mg OD for 5 days and increased budesonide/formoterol to 320/9 mcg BD.

Examination shows RR 24, SpO2 94%, bilateral wheeze. Non-smoker, works outdoors. Non-adherent to ICS due to work demands. I've advised trigger avoidance and provided an action plan. Please assess for add-on therapies (e.g., montelukast) or occupational asthma. Urgent review is needed to prevent hospitalizations.

Contact me at (555) 789-1234 for details. Thank you,

Dr. Ahmed Zaki

Text D: Public Health Advisory – Asthma Triggers

Title: Avoiding Asthma Attacks

Issued by: Metro Health Department, June 2025

Asthma affects 300 million globally, with triggers causing 10% of attacks. Common triggers:

• Pollen: Check daily pollen counts; stay indoors during high levels.
• Air Pollution: Avoid outdoor exercise near traffic; use HEPA filters.
• Smoking: Quit smoking; avoid secondhand smoke.

Management: Use maintenance inhalers daily, carry salbutamol for emergencies. Monitor peak flow; seek help if <60% predicted. Develop an action plan with your doctor. Side effects like thrush are preventable with rinsing.

Emergency: If SOB worsens or inhaler fails, call 111 or visit ER. Contact our asthma helpline (555-456-7890) or educator (ext. 320). Free peak flow meters available for eligible patients. Schools and workplaces should maintain trigger-free zones.

Part B: Workplace Texts

Text 1: Hospital Policy – Patient Confidentiality

Subject: Updated Confidentiality Protocol

To: Nursing Staff

From: Compliance Officer

Date: June 15, 2025

Patient data breaches, affecting 5% of healthcare facilities, compromise trust. Nurses must ensure all patient records are stored securely in the EHR with two-factor authentication. Discuss patient details only in private areas. Consent is required before sharing information with family. Breaches must be reported within 24 hours, with audits starting July 15. Non-compliance, noted in 12% of cases, risks fines and suspension. Training on confidentiality is mandatory, scheduled for July 1–2; register by June 28 via the portal. Use encrypted devices for remote access. Contact the Compliance Officer (ext. 410) for reporting templates or guidance. Educate patients on their privacy rights to enhance cooperation.

Text 2: Antibiotic Stewardship Protocol

Subject: Antibiotic Prescribing Guidelines

To: Pharmacy Staff

From: Infection Control Unit

Date: June 16, 2025

Antibiotic resistance causes 1.3 million deaths annually. Pharmacists must verify antibiotic prescriptions (e.g., amoxicillin) against local resistance patterns, documented in the EHR. Narrow-spectrum agents are preferred; broad-spectrum use requires infectious disease approval. Patients need counseling on adherence and side effects. Compliance data is due by July 20 for audits starting July 16. Non-compliance, observed in 15% of cases, fuels resistance. Training on stewardship is mandatory, scheduled for July 4; register by July 1. Report inappropriate prescribing within 12 hours. Contact the Infection Control Unit (ext. 520) for guidelines or support. Provide patients with disposal instructions to prevent misuse. Document all actions to ensure accountability.

Text 3: Post-Operative Mobility Procedure

Subject: Mobility After Hip Surgery

To: Physiotherapy Staff

From: Orthopedic Department

Date: June 17, 2025

Delayed mobility post-hip surgery increases complication risks by 20%. Physiotherapists must initiate early mobility (e.g., bed-to-chair transfers) within 24 hours post-op, using assistive devices (walkers, crutches). Assess fall risk (Berg Balance Scale) pre-mobilization. Progress must be logged in the EHR, with reviews every 48 hours. High-risk patients (e.g., >70 years) need bed rails. Compliance data is due by July 25 for audits starting July 17. Non-compliance delays recovery. Training on mobility protocols is mandatory, scheduled for July 6; register by July 3. Provide patients with home exercise plans. Contact the Orthopedic Department (ext. 630) for equipment or protocols. Educate families on safety to prevent falls.

Text 4: Stroke Patient Communication Guide

Title: Supporting Stroke Patients

Issued by: Speech Therapy Department

Date: June 18, 2025

Stroke impairs communication in 30% of patients, affecting recovery. Speech therapists must use visual aids (e.g., picture boards) and short sentences to support patients with aphasia. Conduct assessments (Boston Diagnostic Aphasia Examination) within 48 hours post-stroke. Therapy plans must be logged in the EHR, with weekly updates. High-risk patients need family involvement. Compliance data is due by July 30 for audits starting July 18. Non-compliance hinders progress. Training on communication strategies is mandatory, scheduled for July 8; register by July 5. Provide patients with communication tools. Contact the Speech Therapy Department (ext. 740) for resources or support. Encourage teletherapy for accessibility.

Text 5: Oral Cancer Screening Campaign

Subject: Oral Cancer Awareness

To: Dental Staff

From: Public Health Coordinator

Date: June 19, 2025

Oral cancer, linked to tobacco and alcohol, has a 50% survival rate if detected late. Dentists must offer free screenings (visual and palpation exams) during routine visits, targeting high-risk patients (smokers, >40 years). Results must be logged in the EHR, with referrals to oncologists for suspicious findings. Compliance data is due by August 5 for audits starting July 19. Non-compliance, noted in 10% of clinics, delays diagnosis. Training on screening is mandatory, scheduled for July 10; register by July 7. Provide patients with prevention leaflets. Contact the Public Health Coordinator (ext. 850) for resources or referral pathways. Promote campaigns to increase uptake.

Text 6: Elderly Fall Prevention Memo

Subject: Fall Risk Reduction

To: Occupational Therapy Staff

From: Geriatric Services

Date: June 20, 2025

Falls cause 40% of elderly injuries, leading to hospitalizations. Therapists must conduct home safety assessments (e.g., remove rugs, install grab bars) for patients >65 years. Recommend balance exercises (e.g., tai chi) and review medications for dizziness risks. Assessments must be logged in the EHR, with follow-ups in 6 weeks. Compliance data is due by August 10 for audits starting July 20. Non-compliance increases fall risk. Training on fall prevention is mandatory, scheduled for July 12; register by July 9. Provide patients with safety checklists. Contact Geriatric Services (ext. 960) for tools or support. Educate families on monitoring.

Part C: Research Articles

Text 1: AI in Healthcare Policy

Authors: David Blumenthal, MD, MPP, et al.

Published: November 7, 2024, NEJM (Adapted)

Artificial intelligence (AI) is transforming healthcare, with applications in diagnostics, treatment planning and administration. AI tools, like diagnostic algorithms, improve accuracy by 15% for conditions like pneumonia. However, ethical and regulatory challenges persist. This policy perspective examines AI's integration, focusing on patient safety, equity and clinician trust.

AI's diagnostic tools analyze imaging and EHR data, outperforming radiologists in 10% of lung cancer cases. Predictive models reduce hospital readmissions by 20% for heart failure patients. Administrative AI cuts scheduling errors by 30%. Yet, 25% of AI tools show bias (e.g., underdiagnosing minorities), risking inequity. Regulatory gaps exist; only 50% of AI tools are FDA-approved, raising safety concerns.

Stakeholders (clinicians, policymakers) advocate for transparent algorithms, with 80% supporting open-source models. Training enhances clinician trust, reducing resistance by 40%. Costs are high ($500,000–$1 million/tool), limiting adoption in low-resource settings. Subgroup analyses show rural hospitals lag in AI use (10% vs. 40% urban).

Strengths include AI's scalability and data-driven insights. Limitations involve bias, cost and clinician skepticism. Future policies should mandate bias audits and subsidies for rural adoption. AI could save $150 billion annually by 2030 if integrated ethically. Clinicians must balance AI reliance with clinical judgment, ensuring patient-centered care.

Text 2: Semaglutide for Heart Failure

Authors: Mikhail N. Kosiborod, MD, et al.

Published: December 19, 2024, NEJM (Adapted)

Heart failure with preserved ejection fraction (HFpEF) affects 30 million adults, causing dyspnea and reduced quality of life (QoL). Semaglutide, a GLP-1 receptor agonist, reduces weight and inflammation, potentially benefiting HFpEF. The STEP-HFpEF trial evaluated semaglutide's efficacy in HFpEF patients with obesity, focusing on symptoms and functional outcomes.

The trial was a randomized, double-blind, placebo-controlled study involving 1,000 patients (mean age 62.5 years, BMI 34.2) in North America and Europe. Participants received semaglutide (2.4 mg weekly) or placebo for 52 weeks. Primary outcome was change in Kansas City Cardiomyopathy Questionnaire (KCCQ score) (0–100, higher better). Secondary outcomes included 6-minute walk distance (6MWD), weight loss, and hospitalization rates.

At 52 weeks, semaglutide improved KCCQ scores by 16.6 points (95% CI, 13.3–19.9; P<0.001) vs. 8.7 points for placebo. 6MWD increased by 20.3 m (95% CI, 15.2–25.4; P<0.001) vs. 5.1 m for placebo. Weight loss was 10.2% (95% CI, 9.0–11.4; P<0.001) vs. 2.5%. Hospitalizations dropped by 30% (RR 0.70; 95% CI, 0.55–0.89; P=0.003). Subgroup analyses showed greater KCCQ improvement in women (18.0 vs. 14.5 points men).

Adverse events included nausea (18% semaglutide vs. 8% placebo) and diarrhea (12% vs. 6%), mostly transient. Serious AEs were rare (3% vs. 2%). Cost-effectiveness showed $45,000 per QALY gained. Limitations include 52-week follow-up and exclusion of non-obese patients, limiting generalizability. Future studies should explore long-term effects and non-obese HFpEF patients. Semaglutide improves symptoms and function in HFpEF, supporting its use in obese patients. Clinicians should monitor gastrointestinal AEs and integrate semaglutide into HFpEF management, with cases projected to rise 20% by 2035.